{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:45:46Z","timestamp":1787262346616,"version":"build-2736575974"},"reference-count":11,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Lactic acidosis is a serious condition often associated with tissue hypoxia or sepsis, but it can also be caused by beta-adrenergic agonists such as albuterol. This report describes a case of albuterol-induced lactic acidosis in a male patient in his 70s with chronic obstructive pulmonary disease exacerbation. The patient presented with progressively worsening dyspnoea and increased albuterol use. During the initial evaluation, an elevated lactate level was observed, which further increased after albuterol treatment in the emergency room. A thorough sepsis workup was performed, yielding negative results, which ultimately led to the diagnosis of albuterol-induced lactic acidosis. After reducing the frequency of albuterol treatments, the patient\u2019s lactate levels normalised. This case underscores the importance of considering medication-induced causes of lactic acidosis, particularly in patients with respiratory conditions who are frequently administered beta-adrenergic agonists. Recognising this under-reported phenomenon can help clinicians avoid unnecessary sepsis workups and ensure more accurate treatment plans.<\/jats:p>","DOI":"10.1136\/bcr-2024-263495","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:05:16Z","timestamp":1745449516000},"page":"e263495","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Recognising and managing albuterol-induced lactic acidosis"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2395-6315","authenticated-orcid":false,"given":"Sujatha","family":"Baddam","sequence":"first","affiliation":[{"name":"Internal Medicine, Huntsville Hospital Health System, Madison, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Muttineni","sequence":"additional","affiliation":[{"name":"Huntsville Hospital Health System, Huntsville, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025082622474639000_18.4.e263495.1","unstructured":"Uptodate . Causes of lactic acidosis. 2020. Available: https:\/\/www.uptodate.com\/contents\/causes-of-lactic-acidosis"},{"key":"2025082622474639000_18.4.e263495.2","unstructured":"Foucher CD , Tubben RE . Lactic acidosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470202\/"},{"key":"2025082622474639000_18.4.e263495.3","doi-asserted-by":"crossref","unstructured":"Kluge S , Heer G , Jarczak D , et al . Laktatazidose \u2013 Update 2018. Dtsch Med Wochenschr 2018;30060277. doi:10.1055\/a-0585-7986","DOI":"10.1055\/a-0585-7986"},{"key":"2025082622474639000_18.4.e263495.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1309483"},{"key":"2025082622474639000_18.4.e263495.5","first-page":"408","article-title":"Beta-Adrenergic Agonist Therapy and Lactic Acidosis","volume":"96","author":"Gluck","year":"1989","journal-title":"Chest"},{"key":"2025082622474639000_18.4.e263495.6","first-page":"1307","article-title":"Stimulation of both beta- and alpha-adrenergicreceptors increases lactate in resting humans","volume":"82","author":"Bellinger","year":"1985","journal-title":"J Appl Physiol"},{"key":"2025082622474639000_18.4.e263495.7","doi-asserted-by":"crossref","unstructured":"Marik PE , Bankov A . Beta-agonist induced hyperlactatemia. Crit Care 2013;17. doi:10.1186\/cc12514","DOI":"10.1186\/cc12514"},{"key":"2025082622474639000_18.4.e263495.8","first-page":"686","article-title":"Albuterol-induced lactic acidosis","volume":"11","author":"Haupt","year":"1983","journal-title":"Crit Care Med"},{"key":"2025082622474639000_18.4.e263495.9","article-title":"Beta-agonist-induced lactic acidosis: an unusual cause of hyperlactataemia","volume":"2013","author":"Theodosiou","year":"2013","journal-title":"BMJ Case Rep"},{"key":"2025082622474639000_18.4.e263495.10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-224090","article-title":"Beware of beta! A case of salbutamol-induced lactic acidosis in severe asthma","volume":"2018","author":"Sharif","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2025082622474639000_18.4.e263495.11","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:47:54Z","timestamp":1756273674000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,23]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bcr-2024-263495"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263495","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}